More recently, ICP immunotherapy failure in this type of cancer was explained by the absence of T cell migration into the tumors, a process that involves the expression of PD-L1 and Gal-9 at the cell surface of the tumor endothelium [51]. The gene discussed is LGALS9; the disease is cancer.